{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:33:16Z","timestamp":1790728396686,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.pharma.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T11:00:54Z","timestamp":1590836454000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Risk evaluation of the use of complementary and alternative medicines in cancer"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4623-8079","authenticated-orcid":false,"given":"S.","family":"Renet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de Chevigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hoacoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-L.","family":"Belkarfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jardin-Szucs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Bezie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jouveshomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharma.2020.05.001_bib0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/annonc\/mdi110","article-title":"Use of complementary and alternative medicine in cancer patients: a European survey","volume":"16","author":"Molassiotis","year":"2005","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.pharma.2020.05.001_bib0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1534735411423920","article-title":"How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis","volume":"11","author":"Horneber","year":"2012","journal-title":"Integr Cancer Ther"},{"issue":"5","key":"10.1016\/j.pharma.2020.05.001_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12032-019-1267-z","article-title":"Interaction between phytotherapy and oral anticancer agents: prospective study and literature review","volume":"36","author":"Clairet","year":"2019","journal-title":"Med Oncol"},{"issue":"12","key":"10.1016\/j.pharma.2020.05.001_bib0020","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1200\/JCO.2004.08.182","article-title":"Herbal remedies in the United States: potential adverse interactions with anticancer agents","volume":"22","author":"Sparreboom","year":"2004","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.pharma.2020.05.001_bib0025","first-page":"1017","article-title":"Use of complementary medicine by cancer patients in a French oncology department","volume":"94","author":"Tr\u00e4ger-Maury","year":"2007","journal-title":"Bull Cancer"},{"key":"10.1016\/j.pharma.2020.05.001_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/1534735419846392","article-title":"Potential interactions of biologically based complementary medicine in gynecological oncology","volume":"18","author":"Drozdoff","year":"2019","journal-title":"Integr Cancer Ther"},{"key":"10.1016\/j.pharma.2020.05.001_bib0035","unstructured":"World Health Organization. WHO global report on traditional and complementary medicine 2019. Luxebourg, 2019.pdf [Internet]. [cit\u00e9 31 mai 2019]. Disponible sur: https:\/\/www.who.int\/traditional-complementary-integrative-medicine\/WhoGlobalReportOnTraditionalAndComplementaryMedicine2019.pdf?ua=1."},{"key":"10.1016\/j.pharma.2020.05.001_bib0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6882-2-8","article-title":"Use of complementary\/alternative therapies by women with advanced-stage breast cancer","volume":"2","author":"Shen","year":"2002","journal-title":"BMC Complement Altern Med"},{"issue":"5","key":"10.1016\/j.pharma.2020.05.001_bib0045","first-page":"483","article-title":"Complementary and alternative medicines taken by cancer patients","volume":"94","author":"Simon","year":"2007","journal-title":"Bull Cancer"},{"issue":"10","key":"10.1016\/j.pharma.2020.05.001_bib0050","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaoncol.2018.2487","article-title":"Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers","volume":"4","author":"Johnson","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pharma.2020.05.001_bib0055","series-title":"Les pratiques de soins non conventionnelles [Internet]","author":"DGS","year":"2019"},{"key":"10.1016\/j.pharma.2020.05.001_bib0060","series-title":"Complementary, alternative, or integrative health: what's in a name? [Internet]","author":"National Center for Complementary and Integrative Health (NCCIH)","year":"2018"},{"issue":"16","key":"10.1016\/j.pharma.2020.05.001_bib0065","first-page":"1247","article-title":"Effects of St. John's Wort on Irinotecan Metabolism","volume":"94","author":"Mathijssen","year":"2002","journal-title":"CancerSpectrum Knowledge Environment"},{"issue":"4","key":"10.1016\/j.pharma.2020.05.001_bib0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clpt.2004.06.007","article-title":"Effect of St John's wort on imatinib mesylate pharmacokinetics","volume":"76","author":"Frye","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharma.2020.05.001_bib0075","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 - D\u00e9marche centr\u00e9e sur le patient: information, conseil, \u00e9ducation th\u00e9rapeutique. Haute Autorit\u00e9 de Sant\u00e9. Website, suivi [Mis en ligne le 25 juin 2015]. [cit\u00e9 31 mai 2019]. Disponible sur: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2040144\/fr\/demarche-centree-sur-le-patient-information-conseil-education-therapeutique-suivi."},{"key":"10.1016\/j.pharma.2020.05.001_bib0080","article-title":"La place des m\u00e9decines compl\u00e9mentaires chez les patients sous chimioth\u00e9rapie\u00a0: \u00e9tude prospective multicentrique r\u00e9alis\u00e9e aupr\u00e8s des patients et des professionnels de sant\u00e9 de canc\u00e9rologie dans 4 h\u00f4pitaux de la r\u00e9gion Rh\u00f4ne-Alpes","author":"Morandini","year":"2010","journal-title":"Th\u00e8se soutenue, Grenoble"},{"issue":"5","key":"10.1016\/j.pharma.2020.05.001_bib0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0002-9610(00)00358-5","article-title":"A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites","volume":"179","author":"Morris","year":"2000","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.pharma.2020.05.001_bib0090","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s13187-013-0542-5","article-title":"Traditional Chinese medicine use among Chinese immigrant cancer patients","volume":"29","author":"Leng","year":"2014","journal-title":"J Cancer Educ"},{"key":"10.1016\/j.pharma.2020.05.001_bib0095","unstructured":"About Herbs, Botanicals & Other Products [Internet]. Memorial Sloan Kettering Cancer Center. [cit\u00e9 31 mai 2019]. Disponible sur: https:\/\/www.mskcc.org\/cancer-care\/diagnosis-treatment\/symptom-management\/integrative-medicine\/herbs."},{"issue":"552","key":"10.1016\/j.pharma.2020.05.001_bib0100","first-page":"45","article-title":"Cancer du sein\u00a0: recommandations sur l\u2019usage de la phytoth\u00e9rapie","volume":"55","author":"Chabosseau","year":"2016","journal-title":"Actual Pharm"},{"key":"10.1016\/j.pharma.2020.05.001_bib0105","series-title":"Prise en charge des effets ind\u00e9sirables de la chimioth\u00e9rapie anticanc\u00e9reuse \u00e0 l\u2019officine par hom\u00e9opathie, aromath\u00e9rapie et phytoth\u00e9rapie.","author":"Carol","year":"2017"},{"key":"10.1016\/j.pharma.2020.05.001_bib0110","unstructured":"Th\u00e9riaque [Internet]. [cit\u00e9 31 mai 2019]. Disponible sur: http:\/\/www.theriaque.org\/apps\/contenu\/accueil.php."},{"key":"10.1016\/j.pharma.2020.05.001_bib0115","unstructured":"Guide des compl\u00e9ments alimentaires | Fondation contre le Cancer [Internet]. [cit\u00e9 31 mai 2019]. Disponible sur: https:\/\/www.cancer.be\/complementsalimentaires."},{"issue":"10","key":"10.1016\/j.pharma.2020.05.001_bib0120","first-page":"1267","article-title":"Prevalence of complementary and alternative medicine use in cancer patients","volume":"15","author":"Bernstein","year":"2001","journal-title":"Oncology (Williston Park)"},{"issue":"10","key":"10.1016\/j.pharma.2020.05.001_bib0125","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.2105\/AJPH.92.10.1648","article-title":"Use of complementary and alternative medicine among persons with diabetes mellitus: results of a national survey","volume":"92","author":"Yeh","year":"2002","journal-title":"Am J Public Health"},{"issue":"5","key":"10.1016\/j.pharma.2020.05.001_bib0130","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1378\/chest.120.5.1461","article-title":"Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis","volume":"120","author":"Blanc","year":"2001","journal-title":"Chest"},{"issue":"20","key":"10.1016\/j.pharma.2020.05.001_bib0135","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/archinte.158.20.2257","article-title":"Patterns of Use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients","volume":"158","author":"Fairfield","year":"1998","journal-title":"Arch Intern Med"},{"issue":"1\u20132","key":"10.1016\/j.pharma.2020.05.001_bib0140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0022-510X(01)00615-3","article-title":"The use of alternative medicine by patients with amyotrophic lateral sclerosis","volume":"191","author":"Wasner","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharma.2020.05.001_bib0145","unstructured":"Alimentation, phytoth\u00e9rapie, compl\u00e9ments alimentaires, etc. quels sont les risques d\u2019interactions avec les th\u00e9rapies orales? [Internet]. [cit\u00e9 5 juin 2019]. Disponible sur: https:\/\/www.monreseau-cancerdusein.com\/Dossier\/Article\/mieux-comprendre\/gerer-les-suites-operatoires-les-effets-indes\/effets-indesirables-des-medicaments-interacti\/alimentation-phytotherapie-complements-alimentaires-etc-quels-sont-les-risq?url=\/mieux-comprendre\/gerer-les-suites-operatoires-les-effets-indes\/effets-indesirables-des-medicaments-interacti\/alimentation-phytotherapie-complements-alimentaires-etc-quels-sont-les-risq."},{"key":"10.1016\/j.pharma.2020.05.001_bib0150","first-page":"Doc05","article-title":"Complementary and alternative drug therapy versus science-oriented medicine","volume":"13","author":"Anlauf","year":"2015","journal-title":"Ger Med Sci"},{"key":"10.1016\/j.pharma.2020.05.001_bib0155","series-title":"Safety and security on the Internet: challenges and advances in member states: based on the findings of the second global survey on eHealth","first-page":"86","author":"World Health Organization","year":"2011"},{"issue":"3","key":"10.1016\/j.pharma.2020.05.001_bib0160","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1525-1497.2002.10603.x","article-title":"Patients\u2019 use of the internet for medical information","volume":"17","author":"Diaz","year":"2002","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1016\/j.pharma.2020.05.001_bib0165","doi-asserted-by":"crossref","first-page":"e0122499","DOI":"10.1371\/journal.pone.0122499","article-title":"Patients as partners: a qualitative study of patients\u2019 engagement in their health care. Bayer A, \u00e9diteur","volume":"10","author":"Pomey","year":"2015","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1016\/j.pharma.2020.05.001_bib0170","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JAC.0b013e318249e0fd","article-title":"Patient engagement\u00a0\u2013\u00a0What works?","volume":"35","author":"Coulter","year":"2012","journal-title":"J Ambul Care Manage"},{"issue":"1","key":"10.1016\/j.pharma.2020.05.001_bib0175","article-title":"Patient engagement in research: a systematic review","volume":"14","author":"Domecq","year":"2014","journal-title":"BMC Health Services Research [Internet]"},{"issue":"69","key":"10.1016\/j.pharma.2020.05.001_bib0180","article-title":"Les savoirs des malades peuvent-ils \u00eatre tenus pour des savoirs amateurs?","author":"Jouet","year":"2011","journal-title":"Alliage [Internet]"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450920300687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450920300687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:35:24Z","timestamp":1757720124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450920300687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0003450920300687"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2020.05.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk evaluation of the use of complementary and alternative medicines in cancer","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}